DHS 75.59(28)(c)(c) Emergency contact. Each OTP shall provide the SOTA with the emergency contact information for at least one member of the service. DHS 75.59(28)(d)(d) Medication supply. Each OTP shall keep at least a 10-day supply based on average caseload of methadone and buprenorphine products on site to prepare to receive clients from other facilities in disaster scenarios. DHS 75.59 HistoryHistory: CR 20-047: cr. Register October 2021 No. 790, eff. 10-1-22; correction in (5) (b), (g) , (6) (a) 3. a., 4., (h), (k) 2., (7) (a) (intro.), (9) (a), (10) (c) 12., (12) (b) 2., (d) 2., 7., (h) 1. d. to f., 2. a. to e., (15) (a) 1., (21) (e), (f), (23) (a) made under s. 35.17, Stats., correction in numbering in (25m) made under s. 13.92 (4) (b) 1., Stats., correction in (6) (i) 3. made under s. 13.92 (4) (b) 4., Stats., and (10) (b) (title) created under s. 13.92 (4) (b) 2., Stats., Register October 2021 No. 790. DHS 75.60DHS 75.60 Office-based opioid treatment. DHS 75.60(1)(1) Applicability. This section shall not apply to office-based opioid treatment occurring in any of the following settings: DHS 75.60(1)(a)(a) A treatment service in which all patients receiving medication for addiction are enrolled in a service otherwise certified under this chapter. DHS 75.60(1)(e)(e) A service providing medication for addiction to less than 30 patients. DHS 75.60(2)(2) Service description. In this section, “office-based opioid treatment,” or “OBOT” service means pharmacotherapy for opioid use disorder, delivered in a stand-alone office-based opioid treatment clinic, a private office, or public sector clinic setting, excluding certified settings exempted in s. DHS 75.60 (1) or otherwise certified under this chapter, by practitioners authorized to prescribe outpatient supplies of medications approved by the FDA for the treatment of opioid addiction or dependence, prevention of relapse of opioid addiction or dependence, or both. An OBOT is subject to the oversight of the state opioid treatment authority. OBOT includes treatment with all medications approved by the FDA for such treatment. DHS 75.60(3)(3) Relationship to treatment service general requirements. A service that provides OBOT under this section shall be exempt from the treatment service general requirements in subchapter IV, unless otherwise indicated in this section. DHS 75.60(4)(a)(a) “Drug Addiction Treatment Act of 2000” (DATA 2000) means Title XXXV, Section 3502 of the Children’s Health Act, permits physicians who meet certain qualifications to treat opioid addiction with Schedule III, IV, and V narcotic medications that have been specifically approved by the FDA for that indication. DHS 75.60(4)(b)(b) “DATA 2000 waiver” means an authorization conveyed by SAMHSA and the DEA to a practitioner that permits them to prescribe or administer buprenorphine products to an individual with an opioid use disorder. DHS 75.60(4)(c)(c) “Primary care service” means outpatient general health care services provided by a clinic for regular health care services, preventive care, or for a specific health concern, and includes all of the following: DHS 75.60(4)(c)1.1. Care that promotes and maintains mental and physical health and wellness. DHS 75.60(4)(c)3.3. Screening, diagnosing, and treating acute or chronic conditions caused by disease, injury, or illness. DHS 75.60(4)(c)5.5. Provision of a broad spectrum of preventive and curative health care over a period of time. DHS 75.60(5)(5) State opioid treatment authority. The powers and duties of the SOTA include: DHS 75.60(5)(a)(a) Facilitating the development and implementation of rules, regulations, standards, and evidence-based practices, emerging best practices, or promising practices, to ensure the quality of services delivered by OBOT services. DHS 75.60(5)(b)(b) Acting as a liaison between relevant state and federal agencies. DHS 75.60(5)(c)(c) Reviewing opioid treatment guidelines and regulations developed by the federal government.